VRAX has 36-month beta value of 1.82. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VRAX is 4.05M, and currently, short sellers hold a 2.20% ratio of that float. The average trading volume of VRAX on December 26, 2024 was 1.79M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
VRAX) stock’s latest price update
The stock of Virax Biolabs Group Ltd (NASDAQ: VRAX) has decreased by -10.42 when compared to last closing price of 1.92.Despite this, the company has seen a gain of 2.94% in its stock price over the last five trading days. prnewswire.com reported 2024-12-17 that LONDON, Dec. 17, 2024 /PRNewswire/ — Virax Biolabs Group Limited (NASDAQ: VRAX) (“Virax” or the “Company”), an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases, today announced that Mr. James Foster, Chief Executive Officer of Virax, has issued a letter to shareholders outlining the Company’s plans for 2025 and highlights recent accomplishments.
VRAX’s Market Performance
Virax Biolabs Group Ltd (VRAX) has experienced a 2.94% rise in stock performance for the past week, with a -12.94% drop in the past month, and a -12.06% drop in the past quarter. The volatility ratio for the week is 25.44%, and the volatility levels for the past 30 days are at 12.16% for VRAX. The simple moving average for the past 20 days is -5.91% for VRAX’s stock, with a 2.96% simple moving average for the past 200 days.
VRAX Trading at -10.70% from the 50-Day Moving Average
After a stumble in the market that brought VRAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.89% of loss for the given period.
Volatility was left at 12.16%, however, over the last 30 days, the volatility rate increased by 25.44%, as shares sank -18.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.97% lower at present.
During the last 5 trading sessions, VRAX rose by +1.18%, which changed the moving average for the period of 200-days by +97.70% in comparison to the 20-day moving average, which settled at $1.8265. In addition, Virax Biolabs Group Ltd saw 19.86% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for VRAX
Current profitability levels for the company are sitting at:
- -41.53 for the present operating margin
- 0.32 for the gross margin
The net margin for Virax Biolabs Group Ltd stands at -43.05. The total capital return value is set at -1.22. Equity return is now at value -87.87, with -79.92 for asset returns.
Currently, EBITDA for the company is -6.61 million with net debt to EBITDA at 0.52. When we switch over and look at the enterprise to sales, we see a ratio of 26.23. The receivables turnover for the company is 0.72for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.58.
Conclusion
To put it simply, Virax Biolabs Group Ltd (VRAX) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
